Seeking Alpha

The sell-off in Optimer Pharmaceuticals (OPTR -16.6%) accelerates as the session drags on, with...

The sell-off in Optimer Pharmaceuticals (OPTR -16.6%) accelerates as the session drags on, with losses now well into the double-digits. On top of Needham's downgrade (disappointing Dificid sales may equate to less value for anyone planning an acquisition), Baird chimes in as well, cutting the shares to Neutral from Outperform (price target still $16). (earnings, CC)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)